Compare Fresenius Kabi Onco. with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs IPCA LABS - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. IPCA LABS FRESENIUS KABI ONCO./
IPCA LABS
 
P/E (TTM) x 22.1 24.5 90.2% View Chart
P/BV x 3.1 4.7 66.3% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 FRESENIUS KABI ONCO.   IPCA LABS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
IPCA LABS
Mar-19
FRESENIUS KABI ONCO./
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1761,042 16.9%   
Low Rs79590 13.3%   
Sales per share (Unadj.) Rs37.7298.6 12.6%  
Earnings per share (Unadj.) Rs5.135.0 14.6%  
Cash flow per share (Unadj.) Rs6.749.4 13.6%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.5247.1 17.2%  
Shares outstanding (eoy) m158.23126.35 125.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.42.7 123.6%   
Avg P/E ratio x25.023.3 107.2%  
P/CF ratio (eoy) x18.916.5 114.7%  
Price / Book Value ratio x3.03.3 90.6%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m20,135103,108 19.5%   
No. of employees `0001.213.4 8.6%   
Total wages/salary Rs m7037,874 8.9%   
Avg. sales/employee Rs Th5,176.22,807.0 184.4%   
Avg. wages/employee Rs Th610.4585.8 104.2%   
Avg. net profit/employee Rs Th699.6329.0 212.6%   
INCOME DATA
Net Sales Rs m5,96337,732 15.8%  
Other income Rs m18577 3.1%   
Total revenues Rs m5,98138,309 15.6%   
Gross profit Rs m1,4306,901 20.7%  
Depreciation Rs m2581,824 14.1%   
Interest Rs m-26189 -13.8%   
Profit before tax Rs m1,2165,465 22.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,042 32.8%   
Profit after tax Rs m8064,422 18.2%  
Gross profit margin %24.018.3 131.1%  
Effective tax rate %28.119.1 147.5%   
Net profit margin %13.511.7 115.3%  
BALANCE SHEET DATA
Current assets Rs m5,10223,778 21.5%   
Current liabilities Rs m2,38510,975 21.7%   
Net working cap to sales %45.633.9 134.2%  
Current ratio x2.12.2 98.7%  
Inventory Days Days150104 144.6%  
Debtors Days Days11366 171.8%  
Net fixed assets Rs m5,14820,368 25.3%   
Share capital Rs m158253 62.6%   
"Free" reserves Rs m6,55630,971 21.2%   
Net worth Rs m6,73231,224 21.6%   
Long term debt Rs m9521,409 67.6%   
Total assets Rs m10,38845,507 22.8%  
Interest coverage x-45.830.0 -152.8%   
Debt to equity ratio x0.10 313.6%  
Sales to assets ratio x0.60.8 69.2%   
Return on assets %7.510.1 74.1%  
Return on equity %12.014.2 84.5%  
Return on capital %14.617.3 84.3%  
Exports to sales %74.545.9 162.3%   
Imports to sales %24.816.6 149.2%   
Exports (fob) Rs m4,44117,308 25.7%   
Imports (cif) Rs m1,4776,266 23.6%   
Fx inflow Rs m5,29817,308 30.6%   
Fx outflow Rs m1,7726,266 28.3%   
Net fx Rs m3,52511,042 31.9%   
CASH FLOW
From Operations Rs m1,2744,923 25.9%  
From Investments Rs m-1,204-1,563 77.0%  
From Financial Activity Rs m-196-1,832 10.7%  
Net Cashflow Rs m-1261,528 -8.3%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 9.6 25.3 37.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   42,599 36,892 115.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   DR. DATSONS LABS  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

IPCA LABS share price has hit an all time high at Rs 1,172 (up 5.3%). The BSE HEALTHCARE Index is up by 1.2%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 5.3%) and ABBOTT INDIA (up 3.5%). The top losers include AJANTA PHARMA (down 0.1%) and TORRENT PHARMA (down 0.2%).

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 1.5% (Market Updates)

Nov 18, 2019 | Updated on Nov 18, 2019

IPCA LABS share price has hit an all time high at Rs 1,159 (up 4.0%). The BSE HEALTHCARE Index is up by 1.5%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 4.0%) and ABBOTT INDIA (up 3.1%). The top losers include SYNGENE INTERNATIONAL (down 0.1%) and DISHMAN CARBOGEN AMCIS LTD (down 0.1%).

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SUN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS